Steve Kurzeja Named Chief Revenue Officer of Life Sciences Tech Innovator P360
Veteran pharmaceutical industry executive to lead revenue-generating operations for fast-growing technology developer P360
P360, a leading developer of technology for life sciences companies, announced that veteran pharmaceutical industry executive Steve Kurzeja was appointed the company’s first chief revenue officer (CRO). The fast-growing technology innovator, which to date has experienced 50% Year-Over-Year growth, will rely on Kurzeja to drive better integration and alignment between all of the organization’s revenue-related functions including sales, marketing and customer experience.
Read More: P360 Boosts Its ZING SMS Communication Module With Multimodal Enterprise-Grade Features For…
“The continued digital transformation of the life sciences industry is of critical importance for both patients and care providers because it is the key to improving therapeutic development, time to market and better patient outcomes. I couldn’t think of a better company to be with than P360 for this purpose.”
“Steve’s vast experience leading revenue-generating initiatives for pharmaceutical companies makes him the perfect fit to serve as chief revenue officer of P360,” stated P360 CEO and Founder Anupam Nandwana. “As we continue to grow, it is important that all functions within our organization are aligned towards our revenue-related goals. We are excited for what the next year will bring to our customers, partners, staff and our overall operations.”
Steve Kurzeja comes to P360 with more than 20 years of pharmaceutical commercial industry experience, starting his career at Warner-Lambert and later spending time at Pfizer World HQ in sales operations. He then went on to hold various positions of increasing responsibilities at Warner Chilcott within field sales and operations until Actavis purchased them. Kurzeja then joined Valeant Pharmaceuticals, now Bausch Health, to head up sales operations across several business units and therapeutic classes. While there he was involved in building out Commercial Operations and integrating several strategic acquisitions earning him operational excellence awards and recognition.
Most recently, Kurzeja was instrumental in designing, implementing and supporting commercial infrastructure initiatives at Kyowa Kirin and Biotech Startup, BioXcel Therapeutics. His diverse background and expertise led to successful product launches across various therapeutic classes including rare diseases.
“I am thrilled to be joining such an innovative and passionate group of industry disruptors,” said P360 Chief Revenue Officer Steve Kurzeja. “The continued digital transformation of the life sciences industry is of critical importance for both patients and care providers because it is the key to improving therapeutic development, time to market and better patient outcomes. I couldn’t think of a better company to be with than P360 for this purpose.”
The appointment of Steve Kurzeja as chief revenue officer comes just as P360 announced that its ZING Communication Module has been enhanced with several new enterprise-grade unified communication features. Not only does the ZING unified communications as a service (UCaaS) platform enable life sciences sales teams to send custom branded, templated SMS text messages and other digital assets to healthcare professionals (HCPs), it now features two-way calling, activity tracking, smart automations, flexible integrations and more.
With the ZING UCaaS platform, life sciences sales reps can exchange compliant two-way unified messaging with healthcare professionals without barriers. There are no apps for end-users to download and there are no subscriptions for them to deal with. To HCPs, ZING offers a seamless, hassle-free experience that’s seen as nothing different than their normal method for receiving texts.
ZING is the HCP engagement solution the pharmaceutical industry has been waiting for. Within the first six months of launch, over 50 pharmaceutical organizations have expressed interest in ZING, including each of the top 10 global companies – with five of them currently engaging in deployment discussions.
